{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2Fe557987a-bdc0-4f29-8069-460b9fead3a1","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/e557987a-bdc0-4f29-8069-460b9fead3a1\"></iframe>","title":"The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations","description":"\n        <p>Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations, moderated by Dr Neil Love. Produced by Research To Practice. </p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/WCLC2024/EGFRNSCLC\" rel=\"nofollow\">here</a>. </p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/f13278ca-ddf9-41f0-b294-6fe3e42a6e4d/cover.jpg"}